Condition: Helicobacter Pylori Infection · Dyspepsia · Peptic Ulcer Disease · Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia. The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen. Researchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication. Participants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days. Four weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication. Drug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up. Participants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.
This description comes directly from the study's public registry record.
Syeda Mubashsharah Mahfuz, MBBS · +8801756395139 · mubashsharah68dmc@gmail.com
Md. Ahid Iqbal Khokan, MBBS, MD · +8801722787487 · ahidiqbaldmc65@gmail.com
Always discuss trial participation with your own doctor first.
| Bangabandhu Sheikh Mujib Medical University | Dhaka, Bangladesh | Not Yet Recruiting |
| Bangabandhu Sheikh Mujib Medical University | Dhaka, Bangladesh | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07537634